Proprotein convertase inhibition: Paralyzing the cell's master switches

Biochemical Pharmacology

Volumn 140, Issue , 2017, Pages 8-15

  Klein Szanto, Andres J ^a   Bassi, Daniel E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Molecular therapy; Proprotein convertases; Tumor progression

Indexed keywords

ALPHA 1 ANTITRYPSIN; CHLOROMETHYLKETONE DERIVATIVE; FURIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NANOBODY; PEPTIDOMIMETIC AGENT; POLYARGININE; PRODRUG; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SHORT HAIRPIN RNA; STREPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ISOENZYME; NEW DRUG; TUMOR PROTEIN;

ANTISENSE THERAPY; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONSENSUS SEQUENCE; ENZYME INHIBITION; GENE SILENCING; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BINDING SITE; CELL PROLIFERATION; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; METABOLIC ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ACTIVATION, METABOLIC; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PRODRUGS; PROPROTEIN CONVERTASES; TUMOR BURDEN;

EID: 85020131888     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.04.027     Document Type: Review

References (116)

1. Thomas, G., Furin at the cutting edge: from protein traffic to embryogenesis and disease, Nature reviews. Mol. Cell Biol 3:10 (2002), 753–766.
2. Seidah, N.G., Mowla, S.J., Hamelin, J., Mamarbachi, A.M., Benjannet, S., Toure, B.B., et al. Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. PNAS 96:4 (1999), 1321–1326.
3. Seidah, N.G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S.B., Stifani, S., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. PNAS 100:3 (2003), 928–933.
4. Seidah, N.G., Prat, A., The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11:5 (2012), 367–383.
5. Seidah, N.G., Sadr, M.S., Chretien, M., Mbikay, M., The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J. Biol. Chem. 288:30 (2013), 21473–21481.
6. Bassi, D.E., Fu, J., Lopez de Cicco, R., Klein-Szanto, A.J., Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol. Carcinog. 44:3 (2005), 151–161.
7. Taylor, N.A., Van De Ven, W.J., Creemers, J.W., Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J. 7:10 (2003), 1215–1227.
8. Basak, A., Inhibitors of proprotein convertases. J. Mol. Med. (Berlin, Germany) 83:11 (2005), 844–855.
9. Couture, F., D'Anjou, F., Day, R., On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol. Concepts 2:5 (2011), 421–438.
10. Creemers, J.W., Khatib, A.M., Knock-out mouse models of proprotein convertases: unique functions or redundancy?. Front. Biosci. 13 (2008), 4960–4971.
11. Roebroek, A.J., Taylor, N.A., Louagie, E., Pauli, I., Smeijers, L., Snellinx, A., A., et al. Limited redundancy of the proprotein convertase furin in mouse liver. J. Biol. Chem. 279:51 (2004), 53442–53450.
12. Dubois, C.M., Blanchette, F., Laprise, M.H., Leduc, R., Grondin, F., Seidah, N.G., Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am. J. Pathol. 158:1 (2001), 305–316.
13. Fu, Y., Campbell, E.J., Shepherd, T.G., Nachtigal, M.W., Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol. Cancer Res.: MCR 1:8 (2003), 569–576.
14. Page, R.E., Klein-Szanto, A.J., Litwin, S., Nicolas, E., Al-Jumaily, R., Alexander, P., et al. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell. Oncol. 29:4 (2007), 289–299.
15. D'Anjou, F., Routhier, S., Perreault, J.P., Latil, A., Bonnel, D., Fournier, I., et al. Molecular validation of PACE4 as a target in prostate cancer. Transl. Oncol. 4:3 (2011), 157–172.
16. Couture, F., D'Anjou, F., Desjardins, R., Boudreau, F., Day, R., Role of proprotein convertases in prostate cancer progression. Neoplasia (New York, N.Y.) 14:11 (2012), 1032–1042.
17. Bassi, D.E., Cenna, J., Zhang, J., Cukierman, E., Klein-Szanto, A.J., Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6). Mol. Carcinog. 54:10 (2015), 1122–1131.
18. Bassi, D.E., Zhang, J., Cenna, J., Litwin, S., Cukierman, E., Klein-Szanto, A.J., Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. Neoplasia (New York, N.Y.) 12:7 (2010), 516–526.
19. Malfait, A.M., Arner, E.C., Song, R.H., Alston, J.T., Markosyan, S., Staten, N., et al. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch. Biochem. Biophys. 478:1 (2008), 43–51.
20. Malfait, A.M., Seymour, A.B., Gao, F., Tortorella, M.D., Le Graverand-Gastineau, M.P., Wood, L.S., A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann. Rheum. Dis. 71:6 (2012), 1042–1048.
21. Cordova, Z.M., Gronholm, A., Kytola, V., Taverniti, V., Hamalainen, S., Aittomaki, S., Myeloid cell expressed proprotein convertase FURIN attenuates inflammation. Oncotarget 7:34 (2016), 54392–54404.
22. Schwarz, J., Broder, C., Helmstetter, A., Schmidt, S., Yan, I., Muller, M., et al. Short-term TNFalpha shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17. BBA 1833:12 (2013), 3355–3367.
23. Ichiki, T., Burnett, J.C. Jr, Post-transcriptional modification of pro-BNP in heart failure: is glycosylation and circulating furin key for cardiovascular homeostasis?. Eur. Heart. J. 35:43 (2014), 3001–3003.
24. Lei, X., Basu, D., Li, Z., Zhang, M., Rudic, R.D., Jiang, X.C., et al. Hepatic overexpression of the prodomain of furin lessens progression of atherosclerosis and reduces vascular remodeling in response to injury. Atherosclerosis 236:1 (2014), 121–130.
25. Turpeinen, H., Seppala, I., Lyytikainen, L.P., Raitoharju, E., Hutri-Kahonen, N., Levula, M., et al. A genome-wide expression quantitative trait loci analysis of proprotein convertase subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN expression and blood pressure. Hum. Genet. 134:6 (2015), 627–636.
26. Day, P.M., Schiller, J.T., The role of furin in papillomavirus infection. Fut. Microbiol. 4:10 (2009), 1255–1262.
27. Roebroek, A.J., Umans, L., Pauli, I.G., Robertson, E.J., van Leuven, F., Van de Ven, W.J., et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development (Cambridge, England) 125:24 (1998), 4863–4876.
28. Reichhart, J.M., Tip of another iceberg: Drosophila serpins. Trends Cell. Biol. 15:12 (2005), 659–665.
29. van Tetering, G., Vooijs, M., Proteolytic cleavage of Notch: “HIT and RUN”. Curr. Mol. Med. 11:4 (2011), 255–269.
30. Kim, W., Essalmani, R., Szumska, D., Creemers, J.W., Roebroek, A.J., D'Orleans-Juste, P., et al. Loss of endothelial furin leads to cardiac malformation and early postnatal death. Mol. Cell Biol. 32:17 (2012), 3382–3391.
31. Lopez de Cicco, R., Watson, J.C., Bassi, D.E., Litwin, S., Klein-Szanto, A.J., Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression. Clin. Cancer Res. 10:13 (2004), 4480–4488.
32. Seidah, N.G., Abifadel, M., Prost, S., Boileau, C., Prat, A., The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin/kexin 9. Pharmacol. Rev. 69:1 (2017), 33–52.
33. Elbitar, S., Khoury, P.E., Ghaleb, Y., Rabes, J.P., Varret, M., Seidah, N.G., et al. Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011–2015). Expert Opin. Ther. Pat. 26:12 (2016), 1377–1392.
34. Mazhar, F., Haider, N., Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: an emerging new therapeutic option for the treatment of dyslipidemia. J. Pharmacol. Pharmacother. 7:4 (2016), 190–193.
35. Ito, M.K., Santos, R.D., PCSK9 inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J. Clin. Pharmacol. 57:1 (2017), 7–32.
36. Natarajan, P., Kathiresan, S., PCSK9 inhibitors. Cell, 165(5), 2016, 1037.
37. Alkindi, M., Siminovitch, K.A., Gupta, M., Genest, J., Monoclonal antibodies for the treatment of hypercholesterolemia: targeting PCSK9. Can. J. Cardiol. 32:12 (2016), 1552–1560.
38. Blom, D.J., Dent, R., Castro, R.C., Toth, P.P., PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vasc. Health Risk Manag. 12 (2016), 185–197.
39. Dixon, D.L., Trankle, C., Buckley, L., Parod, E., Carbone, S., Van Tassell, B.W., et al. A review of PCSK9 inhibition and its effects beyond LDL receptors. J. Clin. Lipidol. 10:5 (2016), 1073–1080.
40. Page, M.M., Watts, G.F., PCSK9 inhibitors - mechanisms of action. Australian Prescriber 39:5 (2016), 164–167.
41. Peng, W., Qiang, F., Peng, W., Qian, Z., Ke, Z., Yi, L., et al. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. Int. J. Cardiol. 222 (2016), 119–129.
42. Rallidis, L.S., Lekakis, J., PCSK9 inhibition as an emerging lipid lowering therapy: unanswered questions. Hellenic J. Cardiol. 57:2 (2016), 86–91.
43. Robinson, J.G., Nonstatins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: role in non-familial hypercholesterolemia. Prog. Cardiovasc. Dis. 59:2 (2016), 165–171.
44. Schmidli, R., PCSK9 inhibitors - clinical applications. Australian Prescriber 39:5 (2016), 168–170.
45. White, K., Mohan, C., Rocco, M., PCSK9 inhibition: a promise fulfilled?. Cleve Clin. J. Med. 83:11 Suppl 2 (2016), S36–s44.
46. Lopez-Vallejo, F., Martinez-Mayorga, K., Furin inhibitors: importance of the positive formal charge and beyond. Bioorg. Med. Chem. Lett. 20:14 (2012), 4462–4471.
47. Tian, S., Jianhua, W., Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors. Int. J. Biol. Sci. 6:1 (2010), 89–95.
48. Angliker, H., Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin. J. Med. Chem. 38:20 (1995), 4014–4018.
49. Sarac, M.S., Cameron, A., Lindberg, I., The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect. Immun. 70:12 (2002), 7136–7139.
50. Kacprzak, M.M., Peinado, J.R., Than, M.E., Appel, J., Henrich, S., Lipkind, G., Houghten, R.A., Bode, W., Lindberg, I., Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J. Biol. Chem. 279:35 (2004), 36788–36794.
51. Cameron, A., Appel, J., Houghten, R.A., Lindberg, I., Polyarginines are potent furin inhibitors. J. Biol. Chem. 275:47 (2000), 36741–36749.
52. Fugere, M., Appel, J., Houghten, R.A., Lindberg, I., Day, R., Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol. Pharmacol. 71:1 (2007), 323–332.
53. Ramos-Molina, B., Lick, A.N., Nasrolahi Shirazi, A., Oh, D., Tiwari, R., El-Sayed, N.S., et al. Cationic cell-penetrating peptides are potent furin inhibitors. PloS one, 10(6), 2015, e0130417.
54. Dahms, S.O., Arciniega, M., Steinmetzer, T., Huber, R., Than, M.E., Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism. PNAS 113:40 (2016), 11196–11201.
55. Henrich, S., Lindberg, I., Bode, W., Than, M.E., Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J. Mol. Biol. 345:2 (2005), 211–227.
56. Jiao, G.S., Cregar, L., Wang, J., Millis, S.Z., Tang, C., O'Malley, S., et al. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. PNAS 103:52 (2006), 19707–19712.
57. Ramos-Molina, B., Lick, A.N., Blanco, E.H., Posada-Salgado, J.A., Martinez-Mayorga, K., Johnson, A.T., et al. Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays. Biochem. Pharmacol. 96:2 (2015), 107–118.
58. Becker, G.L., Lu, Y., Hardes, K., Strehlow, B., Levesque, C., Lindberg, I., et al. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J. Biol. Chem. 287:26 (2012), 21992–22003.
59. Levesque, C., Fugere, M., Kwiatkowska, A., Couture, F., Desjardins, R., Routhier, S., P., et al. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J. Med. Chem. 55:23 (2012), 10501–10511.
60. Kwiatkowska, A., Couture, F., Levesque, C., Ly, K., Beauchemin, S., Desjardins, R., Neugebauer, W., et al. Novel insights into structure-activity relationships of N-terminally modified PACE4 inhibitors. ChemMedChem 11:3 (2016), 289–301.
61. Levesque, C., Couture, F., Kwiatkowska, A., Desjardins, R., Guerin, B., Neugebauer, W.A., PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation. Oncotarget 6:6 (2015), 3680–3693.
62. Molloy, S.S., Thomas, L., Kamibayashi, C., Mumby, M.C., Thomas, G., Regulation of endosome sorting by a specific PP2A isoform. J. Cell Biol. 142:6 (1998), 1399–1411.
63. Zhong, M., Munzer, J.S., Basak, A., Benjannet, S., Mowla, S.J., Decroly, E., et al. The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity. J. Biol. Chem. 274:48 (1999), 33913–33920.
64. Lapierre, M., Siegfried, G., Scamuffa, N., Bontemps, Y., Calvo, F., Seidah, N.G., et al. Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1. Cancer Res. 67:19 (2007), 9030–9034.
65. Lopez de Cicco, R., Bassi, D.E., Zucker, S., Seidah, N.G., Klein-Szanto, A.J., Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer Res. 65:10 (2005), 4162–4171.
66. Scamuffa, N., Basak, A., Lalou, C., Wargnier, A., Marcinkiewicz, J., Siegfried, G., et al. Regulation of prohepcidin processing and activity by the subtilisin-like proprotein convertases Furin, PC5, PACE4 and PC7. Gut 57:11 (2008), 1573–1582.
67. Chen, Y., Zhang, J., Deng, M., Furin mediates brain-derived neurotrophic factor upregulation in cultured rat astrocytes exposed to oxygen-glucose deprivation. J. Neurosci. Res. 93:1 (2015), 189–194.
68. Owen, M.C., Brennan, S.O., Lewis, J.H., Carrell, R.W., Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. NEJM 309:12 (1983), 694–698.
69. Jean, F., Stella, K., Thomas, L., Liu, G., Xiang, Y., Reason, A.J., et al. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. PNAS 95:13 (1998), 7293–7298.
70. Dufour, E.K., Denault, J.B., Hopkins, P.C., Leduc, R., Serpin-like properties of alpha1-antitrypsin Portland towards furin convertase. FEBS Lett. 426:1 (1998), 41–46.
71. Tsuji, A., Hashimoto, E., Ikoma, T., Taniguchi, T., Mori, K., Nagahama, M., et al. Inactivation of proprotein convertase, PACE4, by alpha1-antitrypsin Portland (alpha1-PDX), a blocker of proteolytic activation of bone morphogenetic protein during embryogenesis: evidence that PACE4 is able to form an SDS-stable acyl intermediate with alpha1-PDX. J. Biochem. 126:3 (1999), 591–603.
72. Bassi, D.E., Lopez De Cicco, R., Mahloogi, H., Zucker, S., Thomas, G., Klein-Szanto, A.J., Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. PNAS 98:18 (2001), 10326–10331.
73. de Cicco, R.L., Bassi, D.E., Benavides, F., Conti, C.J., Klein-Szanto, A.J., Inhibition of proprotein convertases: approaches to block squamous carcinoma development and progression. Mol. Carcinogen. 46:8 (2007), 654–659.
74. Scamuffa, N., Siegfried, G., Bontemps, Y., Ma, L., Basak, A., Cherel, G., et al. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J. Clin. Invest. 118:1 (2008), 352–363.
75. Anderson, E.D., Thomas, L., Hayflick, J.S., Thomas, G., Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J. Biol. Chem. 268:33 (1993), 24887–24891.
76. Jean, F., Thomas, L., Molloy, S.S., Liu, G., Jarvis, M.A., Nelson, J.A., et al. A protein-based therapeutic for human cytomegalovirus infection. PNAS 97:6 (2000), 2864–2869.
77. Hada, K., Isshiki, K., Matsuda, S., Yuasa, K., Tsuji, A., Engineering of alpha1-antitrypsin variants with improved specificity for the proprotein convertase furin using site-directed random mutagenesis. Protein Eng. Des. Sel. 26:2 (2013), 123–131.
78. Dahms, S.O., Creemers, J.W., Schaub, Y., Bourenkov, G.P., Zogg, T., Brandstetter, H., The structure of a furin-antibody complex explains non-competitive inhibition by steric exclusion of substrate conformers. Sci. Rep., 6, 2016, 34303.
79. Zhu, J., Declercq, J., Roucourt, B., Ghassabeh, G.H., Meulemans, S., Kinne, J., et al. Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochem. J. 448:1 (2012), 73–82.
80. Yamaguchi, Y., Tsumura, H., Miwa, M., Inaba, K., Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15:2 (1997), 144–153.
81. Gentry, L.E., Lioubin, M.N., Purchio, A.F., Marquardt, H., Molecular events in the processing of recombinant type 1 pre-pro-transforming growth factor beta to the mature polypeptide. Mol. Cell Biol. 8:10 (1988), 4162–4168.
82. Osada, S.I., Wright, C.V., Xenopus nodal-related signaling is essential for mesendodermal patterning during early embryogenesis. Development (Cambridge, England) 126:14 (1999), 3229–3240.
83. Rao, D.D., Maples, P.B., Senzer, N., Kumar, P., Wang, Z., Pappen, B.O., et al. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther. 17:11 (2010), 780–791.
84. Nemunaitis, J., Barve, M., Orr, D., Kuhn, J., Magee, M., Lamont, J., et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology 87:1 (2014), 21–29.
85. Senzer, N., Barve, M., Kuhn, J., Melnyk, A., Beitsch, P., Lazar, M., et al. Phase I trial of “bi-shRNAifurin/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol. Ther. 20:3 (2012), 679–686.
86. Ghisoli, M., Barve, M., Mennel, R., Lenarsky, C., Horvath, S., Wallraven, G., et al. Three-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced ewing's sarcoma. Mol. Ther. 24:8 (2016), 1478–1483.
87. Ghisoli, M., Barve, M., Schneider, R., Mennel, R., Lenarsky, C., Wallraven, G., et al. Pilot trial of FANG immunotherapy in Ewing's sarcoma. Mol. Ther. 23:6 (2015), 1103–1109.
88. Oh, J., Barve, M., Matthews, C.M., Koon, E.C., Heffernan, T.P., Fine, B., et al. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol. Oncol. 143:3 (2016), 504–510.
89. Wu, X., Hui, K.M., Induction of potent TRAIL-mediated tumoricidal activity by hFLEX/Furin/TRAIL recombinant DNA construct. Mol. Ther. 9:5 (2004), 674–681.
90. Armeanu, S., Lauer, U.M., Smirnow, I., Schenk, M., Weiss, T.S., Gregor, M., et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 63:10 (2003), 2369–2372.
91. Shan, L.Q., Ma, S., Qiu, X.C., Wang, T., Yu, S.B., Ma, B.A., et al. A novel recombinant immuno-tBid with a furin site effectively suppresses the growth of HER2-positive osteosarcoma cells in vitro. Oncology Rep. 25:2 (2011), 325–331.
92. Wang, T., Zhao, J., Ren, J.L., Zhang, L., Wen, W.H., Zhang, R., et al. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res. 67:24 (2007), 11830–11839.
93. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, N.Y.) 244:4905 (1989), 707–712.
94. Kapitanovic, S., Radosevic, S., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112:4 (1997), 1103–1113.
95. Osman, I., Mikhail, M., Shuch, B., Clute, M., Cheli, C.D., Ghani, F., et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J. Urol. 174:6 (2005), 2174–2177.
96. Turken, O., Kunter, E., Cermik, H., Isitmangil, T., Kandemir, G., Yaylaci, M., et al. Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC). Neoplasma 50:4 (2003), 257–261.
97. Jia, L.T., Zhang, L.H., Yu, C.J., Zhao, J., Xu, Y.M., Gui, J.H., et al. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res. 63:12 (2003), 3257–3262.
98. Wang, S.Y., Chen, B., Zhan, Y.Q., Xu, W.X., Li, C.Y., Yang, R.F., et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J. Hepatol. 41:2 (2004), 267–273.
99. Weldon, J.E., Skarzynski, M., Therres, J.A., Ostovitz, J.R., Zhou, H., Kreitman, R.J., et al. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A. Bioconjugate Chem. 26:6 (2015), 1120–1128.
100. Igney, F.H., Krammer, P.H., Death and anti-death: tumour resistance to apoptosis, nature reviews. Cancer 2:4 (2002), 277–288.
101. Igney, F.H., Krammer, P.H., Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71:6 (2002), 907–920.
102. Zhu, X., Zhou, A., Dey, A., Norrbom, C., Carroll, R., Zhang, C., et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. PNAS 99:16 (2002), 10293–10298.
103. Benzinou, M., Creemers, J.W., Choquet, H., Lobbens, S., Dina, C., Durand, E., et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat. Genet. 40:8 (2008), 943–945.
104. Kilpelainen, T.O., Bingham, S.A., Khaw, K.T., Wareham, N.J., Loos, R.J., Association of variants in the PCSK1 gene with obesity in the EPIC-Norfolk study. Hum. Mol. Gen. 18:18 (2009), 3496–3501.
105. Loffler, D., Behrendt, S., Creemers, J.W., Klammt, J., Aust, G., Stanik, J., et al. Functional and clinical relevance of novel and known PCSK1 variants for childhood obesity and glucose metabolism. Mol. Metab. 6:3 (2017), 295–305.
106. Nordang, G.B., Busk, O.L., Tveten, K., Hanevik, H.I., Fell, A.K., Hjelmesaeth, J., et al. Next-generation sequencing of the monogenic obesity genes LEP, LEPR, MC4R, PCSK1 and POMC in a Norwegian cohort of patients with morbid obesity and normal weight controls. Mol. Genet. Metab., 2017.
107. Wang, L., Sui, L., Panigrahi, S.K., Meece, K., Xin, Y., Kim, J., et al. PC1/3 deficiency impacts pro-opiomelanocortin processing in human embryonic stem cell-derived hypothalamic neurons. Stem Cell Rep. 8:2 (2017), 264–277.
108. Leak, T.S., Keene, K.L., Langefeld, C.D., Gallagher, C.J., Mychaleckyj, J.C., Freedman, B.I., et al. Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population. Mol. Genet. Metab. 92:1–2 (2007), 145–150.
109. Iamsaard, S., Vanichviriyakit, R., Hommalai, G., Saewu, A., Srakaew, N., Withyachumnarnkul, B., et al. Enzymatic activity of sperm proprotein convertase is important for mammalian fertilization. J. Cell. Physiol. 226:11 (2011), 2817–2826.
110. Mbikay, M., Tadros, H., Ishida, N., Lerner, C.P., De Lamirande, E., Chen, A., et al. Impaired fertility in mice deficient for the testicular germ-cell protease PC4. PNAS 94:13 (1997), 6842–6846.
111. Marchesi, C., Essalmani, R., Lemarie, C.A., Leibovitz, E., Ebrahimian, T., Paradis, P., et al. Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. J. Mol. Med. (Berlin, Germany) 89:11 (2011), 1103–1111.
112. Rousselet, E., Benjannet, S., Marcinkiewicz, E., Asselin, M.C., Lazure, C., Seidah, N.G., Proprotein convertase PC7 enhances the activation of the EGF receptor pathway through processing of the EGF precursor. J. Biol. Chem. 286:11 (2011), 9185–9195.
113. Wetsel, W.C., Rodriguiz, R.M., Guillemot, J., Rousselet, E., Essalmani, R., Kim, I.H., et al. Disruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice. PNAS 110:43 (2013), 17362–17367.
114. Bergeron, E., Vincent, M.J., Nichol, S.T., Crimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivity. J. Virol. 81:23 (2007), 13271–13276.
115. Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., Seidah, N.G., Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J. Biol. Chem. 277:13 (2002), 11265–11275.
116. Basak, A., Palmer-Smith, H., Mishra, P., Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation. Protine Pept. Lett. 19:6 (2012), 575–585.